
Video Introducing myself and Objectives of the Course
Description of key facts about the Regulation
Rationale and Summary of changes
Definitions of Key Terms used in the Regulation
Describes submission principles, CTIS overview, CTIS Sponsor workspace, CTIS sponsor roles, content of Part I and II application dossiers and choice of Reporting Member State
Describes validation and assessment (part I and II) processes and timelines
Describes the decision process and timelines, decision rules and scenarios in case of non favourable decision.
Describes the Substantial Modification process for Part I and II and associated timelines, and differences from the initial application.
Describes the process and timelines to add a member state in an ongoing clinical trial.
Describes the safety and other reporting obligations during the life cycle of clinical trials through the CTIS
A guide on how to use the CTIS training material provided by EMA
Review the most critical FAQs that will enable you to implement/use the regulation more efficiently.
1) Recommendation paper on frequent issues identified during assessment of Part I and Part II (Version 1.0 October 2025).
This recommendation paper is a dynamic and evolving document, subject to periodic updates to reflect on the experience gained with ongoing assessments of Parts I and II, incorporating current regulatory insights and feedback to address identified issues.
2) What are the criteria regarding the selection of a reporting Member State as per Article 85(2)(c) of the Clinical Trials Regulation?
Conclusion and Final Advices / Perspective
Updates:
[February 2026]: Added Role Play exercise
[December 2025]: Completed Q&A section with 2 EMA documents
[November 2025]: English captions reviewed and improved
[October 2025]: Lecture 15: Q&A Log updated, Walk in Clinic EMA link added
[November 2024]: Lecture 2: Updated key facts
[January 2024]: Lecture 14 - CTIS Training material catalogue updated with latest information
[March 2023]: Training document material from EMA updated and lecture 14 updated accordingly; New Q&A document from the CTIS/CTR query management working group attached (lecture 15)
---
On 31st January 2023, the Clinical Trial Regulation (CTR) 536/2014 came into force in the European Union (EU) and repealed the Clinical Trials Directive 2001/20/EC. With this Regulation, the EU harmonises the procedures for carrying out clinical trials across the EU states and simplifies the clinical trial approval process through a Clinical Trials Information System (CTIS).
This course provides clinical research professionals in Sponsor and CRO organizations as well as investigational sites and study staff with an essential understanding of the CTR to help implement and comply with it.
The programme highlights the most important of these key requirements and how these are impacting all EU as well as non-EU sponsors conducting clinical trials in the EU.
My name is Dr. Vincent Baeyens PhD, I have more than 20 years of experience in running Clinical Trials in Global and mid-size Pharma and Biotech settings.
Benefits of attending this course include:
Gain an overview of the Clinical Trial Regulation (CTR) to conduct trials in the EU
Understand why changes to the Directive 2001/20/EC were made
Learn and understand the timeline for CTR introduction and transition period
Learn the essential definitions of terms under the CTR
Understand how the Clinical Trials Information System (CTIS) is set up
Understand the submission process of clinical trials in the CTIS
Understand the validation, assessment and decisions process of clinical trials under the CTR
Learn the process to submit a Substantial Modification of the protocol
Learn the process to submit a new Member State in an ongoing study
Identify the safety and other reporting obligations
Grasp the risks and challenges associated with the CTR in sponsor organizations
Prepare a high-level submission planning under CTR
Quizzes and assignments are proposed along your journey to test your knowledge.
To facilitate the learning of beginner students, the course has been broken up on purpose in small lectures. If you are a more advanced student, you can increase the speed of lecture to learn the course at your desired pace.
Important remark: Please note that this course does not go into the technicalities of the CTIS. References to adequate resources on the topic are provided.
Feel free to look at the content of the course to know more and contact me any time if you have any questions!
I am looking forward to seeing you inside the course!
Sincerely,
Vincent